Amicus Therapeutics, Inc.
FOLDNASDAQHealthcare
$14.49
+$0.00(+0.00%)
Market Cap$4.5B
P/E Ratio—
52W High$14.5
52W Low$5.51
Amicus Therapeutics, Inc. (FOLD) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · FOLD · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.63B | $0.53B | $0.40B | $0.33B | $0.31B |
| Cost of Revenue | $0.08B | $0.05B | $0.04B | $0.04B | $0.03B |
| Gross Profit | $0.55B | $0.48B | $0.36B | $0.29B | $0.27B |
| Gross Margin %(computed) | 87.32% | 89.98% | 90.65% | 88.28% | 88.72% |
| Operating Expenses | |||||
| R&D Expenses | $0.14B | $0.11B | $0.15B | $0.28B | $0.27B |
| G&A Expenses | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Total Operating Expenses | $0.52B | $0.45B | $0.44B | $0.50B | $0.48B |
| Operating Income | $0.03B | $0.02B | ($0.08B) | ($0.21B) | ($0.21B) |
| Operating Margin %(computed) | 5.44% | 4.71% | -19.33% | -64.43% | -67.57% |
| Interest Income | $0.00B | $0.01B | $0.01B | $0.00B | $0.00B |
| Interest Expense | $0.05B | $0.05B | $0.05B | $0.04B | $0.03B |
| Income Before Tax | $0.00B | ($0.03B) | ($0.15B) | ($0.24B) | ($0.24B) |
| Income Tax Expense | $0.03B | $0.03B | $0.00B | ($0.01B) | $0.01B |
| Net Income | ($0.03B) | ($0.06B) | ($0.15B) | ($0.24B) | ($0.25B) |
| Net Margin %(computed) | -4.27% | -10.62% | -37.96% | -71.85% | -81.98% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-0.09 | $-0.18 | $-0.51 | $-0.82 | $-0.92 |
| Wtd Avg Shares | 0.31B | 0.30B | 0.30B | 0.29B | 0.27B |
| EBITDA | $0.05B | $0.03B | ($0.09B) | ($0.20B) | ($0.20B) |
| EBITDA Margin %(computed) | 8.48% | 5.56% | -23.06% | -60.62% | -66.40% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · B
Explore more Amicus Therapeutics, Inc. data
About Amicus Therapeutics, Inc. (FOLD) Income Statement
Amicus Therapeutics, Inc. (FOLD) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, FOLD reported revenue of $0.63B, gross profit of $0.55B (gross margin 87.32%), and net income of ($0.03B) — a net profit margin of -4.27%.
Frequently asked questions
FOLD · 4 questionsAmicus Therapeutics, Inc. (FOLD) reported revenue of $0.63B for 2025, up 20.0% year-over-year.
FOLD revenueFOLD salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08